Loading stock data…
Novavax, Inc. (NVAX)
$10.19-0.03 (-0.29%)
Market ClosedLast close Sep 8
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Novavax, Inc. in the Healthcare sector is trading at $10.19 with a market capitalization of $1.7B. Wall Street consensus targets $14.00 (9 analysts), implying a +37.4% move over the next 12 months. The stock is currently 15% below its 52-week high of $11.97, remaining 19.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +37.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $139.51M↓ | $147.14M↑ | $70.44M↓ | $239.24M↓ | $666.65M |
| Gross Profit | $108.82M↓ | $125.03M↑ | $48.95M↓ | $223.91M↓ | $652.54M |
| Operating Income | -$15.43M↓ | $15.04M↑ | -$80.98M↓ | $101.07M↓ | $515.51M |
| Net Income | -$9.49M↓ | $17.53M↑ | -$202.38M↓ | $106.51M↓ | $518.65M |
Peer Comparison
JNJUNHPFE
Fundamentals
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-1...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.37
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
60.68%
Volume
Today's trading volume
4.22M
Recent News
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 25.1% over the past six months, topping the S&P 500 by 13.1 percentage points.
Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?
Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.
How Expanded Nuvaxovid Royalties and Partner-led Execution Could Shape Novavax’s (NVAX) Investment Narrative
Novavax reported that partners Sanofi and Takeda have secured approvals for an updated Nuvaxovid formulation targeting the SARS-CoV-2 XFG variant for the 2026–2027 vaccination season across the U.S., European Union, Japan, and other major markets. These approvals allow Novavax to participate in the upcoming COVID-19 vaccination season primarily through royalties and milestones, while its partners shoulder the commercial execution and infrastructure burden. We'll now examine how Novavax’s...
Novavax (NVDA) Following Updated Nuvaxovid Approval Faces A Wide Fair Value Debate
Novavax (NVAX) drew fresh attention after announcing that partners secured approvals for an updated Nuvaxovid formulation targeting the SARS CoV 2 XFG variant for the 2026 to 2027 vaccination season. The news has arrived after a mixed period for Novavax’s stock. The share price is up 26.16% over the past 30 days and 29.87% year to date, yet down 15.59% over 90 days. The 1 year total shareholder return sits at 23.96%, while the 5 year total shareholder return reflects a steep 96.32% decline,...
Has Novavax (NVAX) Fallen Far Enough To Look Cheap?
Novavax stock has delivered a sharp 5 year decline alongside a recent rebound, and the broader valuation checks now point to a mixed picture rather than a clear bargain or clear overvaluation at the current price. The share price return over 5 years is down 96.3%, which signals that long term holders have absorbed very heavy losses despite the recent bounce. Future demand for Novavax products and the company’s ability to convert that demand into steady cash flow can support the equity story,...